Physician profile
Aaron Tabor
NPI 1194080424
$2,228.94
in general payments reported to CMS, 2019-2025
15 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $1,089 · 2024: $809 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.85 |
| Education | $103.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.57 | 2022-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $342.46 | 2022-2024 | Spravato, Invega Sustenna |
| Corium, LLC | $314.63 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $248.35 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $185.77 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $185.33 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Harmony Biosciences LLC | $174.29 | 2023-2024 | Wakix |
| Idorsia Pharmaceuticals US INC | $111.89 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.52 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $59.15 | 2023-2025 | Auvelity |
| Brainsway USA INC | $51.55 | 2023 | |
| Neurocrine Biosciences, INC. | $43.12 | 2022-2023 | Ingrezza |
| Alkermes, INC. | $23.87 | 2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $16.76 | 2024 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $14.68 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Tabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.